Efficacy and safety of two treatment combinations of hypertension in very elderly patients

Roberto Fogari, Annalisa Zoppi, Amedeo Mugellini, Luca Corradi, Pierangelo Lazzari, Paola Preti, Giuseppe Derosa

Research output: Contribution to journalArticlepeer-review


The study compared valsartan/amlodipine combination with irbesartan/hydrochlorothiazide (HCTZ) combination in very elderly hypertensives. After a 4-week placebo period, 94 hypertensives, aged 75-89 years were randomized to valsartan 160 mg/amlodipine 5 mg or irbesartan 300 mg/HCTZ 12.5 mg for 24 weeks according to a prospective, parallel group study. After 4 weeks amlodipine or HCTZ was doubled in non-responders. Patients were checked every 4 weeks. At each visit clinical sitting, lying and standing blood pressure (BP), systolic BP (SBP) and diastolic BP (DBP) were evaluated, and an electrocardiogram was performed. At the end of the placebo period and of the treatment period a non-invasive 24-h ambulatory BP monitoring (ABPM) was performed and electrolytes and uric acid were evaluated. Both combinations significantly reduced ambulatory BP. In the valsartan/amlodipine group the mean reduction (-29.9/-15.6 for 24 h, -28.6/-14.5 mmHg for day-time and -26.2/-17.4 mmHg for night-time SBP/DBP) was similar to that of the irbesartan/HCTZ group (-29.6/-15.4 for 24 h, -29.3/-14.9 mmHg for day-time and -25.4/-16.9 mmHg for night-time SBP/DBP). Both combinations significantly reduced clinical sitting and lying BP values with no difference between treatments. BP changes from lying to standing position were significantly greater in the irbesartan/HCTZ group (-17.2/-9.1 mmHg) than in the valsartan/amlodipine group (-10.1/-1.9 mmHg, p <0.05 for SBP and p <0.01 for DBP vs. irbesartan/HCTZ). Potassium significantly decreased and uric acid significantly increased (-0.4 mmol/l, p <0.05 and +0.5 mg/dl, p <0.05 vs. baseline, respectively) only in the irbesartan/HCTZ group. In conclusion, both combinations were similarly effective in reducing ambulatory and clinical BP in very elderly hypertensives. However, valsartan/amlodipine offered some advantages in terms of less pronounced BP orthostatic changes and absence of metabolic adverse effects.

Original languageEnglish
Pages (from-to)401-405
Number of pages5
JournalArchives of Gerontology and Geriatrics
Issue number3
Publication statusPublished - May 2009


  • Amlodipine
  • Elderly hypertensive patient
  • Hypertension
  • Valsartan

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology
  • Health(social science)
  • Gerontology


Dive into the research topics of 'Efficacy and safety of two treatment combinations of hypertension in very elderly patients'. Together they form a unique fingerprint.

Cite this